ENSC Earnings Date: Nov 13, 2026 (Estimated) — Ensysce Biosciences, Inc.
NASDAQ
Updated
When is ENSC's next earnings date?
Ensysce Biosciences, Inc. (ENSC) is expected to report Q3 2026 earnings on Friday, November 13, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.12 on revenue of $1.2M.
How did ENSC do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Ensysce Biosciences, Inc. posted EPS of -$0.20 versus the -$0.20 estimate, an in-line result. Revenue was $1.2M against a $1.2M estimate. The stock's 1-day post-earnings move was +14.7%.
How much does ENSC stock move after earnings?
ENSC beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.4% (up or down) in the day after earnings.
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.20 | -0.20 | +60.00% | $1.2M | ➖ Inline | +14.75% | +8.41% | +38.13% |
| 2026-05-15 | Q1 2026 | -0.73 | -0.52 | +28.77% | $960,999 | ✅ Beat | +13.17% | +13.75% | -0.75% |
| 2026-03-30 | Q4 2025 | -1.26 | -0.75 | +40.48% | $1.9M | ✅ Beat | +4.77% | +12.08% | -29.71% |
| 2025-11-14 | Q3 2025 | -0.90 | -1.29 | -43.33% | $493,104 | ❌ Miss | -4.85% | -22.82% | -42.72% |
| 2025-08-13 | Q2 2025 | -1.17 | -0.79 | +32.48% | $1.4M | ✅ Beat | -4.19% | -3.95% | -1.86% |
| 2025-03-10 | Q4 2024 | -1.95 | -2.90 | -48.72% | $1.3M | ❌ Miss | -3.78% | -22.51% | -60.26% |
| 2024-08-14 | Q2 2024 | -5.85 | -3.30 | +43.59% | $181,797 | ✅ Beat | +0.79% | +4.02% | -16.44% |
| 2024-05-13 | Q1 2024 | -13.95 | -8.25 | +40.86% | $305,722 | ✅ Beat | -5.06% | +26.38% | -8.39% |
Showing last 8 quarters.